DOCSLIB.ORG

Curriculum Vitae - 11/01/2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae - 11/01/2017 CURRICULUM VITAE - 11/01/2017 NAME: James Francis Howard, Jr., M.D. OFFICE ADDRESS: Department of Neurology 2200 Physicians Office Bldg., CB#7025 170 Manning Drive The University of North Carolina School of Medicine Chapel Hill, NC 27599-7025 E-MAIL: [email protected] TELEPHONE: Home: on request Office: 919.966.8168 Admin: 919.966.9281 EMG Laboratory 984.974.1686 Facsimile: 919.966.2922 EDUCATION: • Research Associate in Neuromuscular Disease, University of Virginia School of Medicine, Charlottesville, Virginia, 1978 — 1979 • Resident, Neurology, University of Virginia Hospital, Charlottesville, Virginia, 1975 — 1978 • Intern, Internal Medicine, Albany Medical Center Hospital, Albany, New York, 1974 — 1975 • M.D., University of Vermont School of Medicine, Burlington, Vermont, 1974 • B.A. (Special Honors in Anatomy), University of Vermont, Burlington, Vermont, 1970 EMPLOYMENT HISTORY: • Professor of Neurology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; July 1, 1992 to present James F. Howard Distinguished Professor of Neuromuscular Disease, November, 2003 • Adjunct Professor of Allied Health Sciences, University of North Carolina School of Medicine, Chapel Hill, North Carolina; October 1, 2011 to present • Adjunct Professor of Clinical Sciences (Neurology), North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, January 1, 2005 to present • Associate Professor of Neurology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; July 1, 1985 through June 30, 1992 • Assistant Professor of Neurology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; July 1, 1979 through June 30, 1985 • Instructor in Neuromuscular Disease, University of Virginia School of Medicine, Charlottesville, Virginia; July 1, 1978 through June 30, 1979 Curriculum Vitae November 6, 2017 Howard, James F., Jr. Page 2 CERTIFICATION AND LICENSURE: • Diplomate, Professional Ski Instructors of America (formerly the United States Eastern Amateur Ski Association), 1969 (currently inactive) • Diplomate, National Board of Medical Examiners, 1975 • Diplomate, American Board of Psychiatry and Neurology, 1980 • Diplomate, American Board of Electrodiagnostic Medicine, 1989 (#0412) • Licensed M.D., Virginia (#0101030059) 1978; North Carolina (#23383) 1979 HOSPITAL APPOINTMENTS: • Attending Physician, University of North Carolina Hospitals, July 1979 to present PROFESSIONAL SOCIETIES: • American Academy of Neurology, 1975 to present Fellow, 1986 to present Active, 1979 — 1986 Junior, 1975 — 1979 • American Association of Neuromuscular & Electrodiagnostic Medicine (formerly the American Association of Electrodiagnostic Medicine and American Association of Electromyography and Electrodiagnosis), 1981 to present Active, 1981 — 1989 Fellow member by examination, 1989 to present Board of Directors, 2002 — 2005 • American Board of Electrodiagnostic Medicine Board of Directors, 2008 — present Examiner, 2002, 2003, 2009 Exam Supervisor, 2009, 2010, 2012 — 2014 • American Medical Association, 1979 to present • American Neurological Association, 1997 to present • International Brain Research Organization/World Federation of Neuroscientists, 1980 to present • Myasthenia Gravis Foundation of America Medical/Scientific Advisory Board, 1979 to present Chair, 2003 — 2005 Vice Chair, 2001 — 2003 Secretary, 1999 — 2001 • New York Academy of Sciences, 1980 to present • North Carolina Medical Society, 1979 to present Chair, Neurology Section, 1994 • North Carolina Neurological Society, 1979 to present President, 1994 Vice President, 1993 Board of Directors, 2000 — 2009 • Orange-Durham County Medical Society, 1979 to present • Society for Neurosciences, 1980 to present • Professional Ski Instructors of America, (formerly the United States Eastern Amateur Ski Association), member by examination, 1969 — 1980; currently inactive status Curriculum Vitae November 6, 2017 Howard, James F., Jr. Page 3 EDITORIAL BOARDS • Associate Editor (founding), Journal of Clinical Neuromuscular Disease, Lippincott, Williams & Wilkins, 1998 — 2006 • Member, Editorial Board, IgNews: Current Topics in Immunoglobulin Research and Therapy, American Red Cross, 2002 — 2004 GRANTS FUNDED (ACTIVE): • Principal Site Investigator: Safety and Efficacy Study of RA101495 in Subjects with Generalized Myasthenia Gravis. Ra Pharmaceuticals Inc. 2017 – 2019. • Site Investigator: A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy. Vertex Pharmaceuticals Inc. 2017 – 2019. • Global Lead Principal Investigator: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness. Argenx BVBA. 2017 – 2019. • Principal Site Investigator: Investigations into the role of autoantibodies to the LRP4 protein in patients with Myasthenia Gravis. NIH/Georgia Health Sciences University. 2016 – 2019 • Co-Investigator: Comp B-Surveillance and Research of Muscular Dystrophy and Neuromuscular Disorders. U01DD001116, Centers for Disease Control, and Prevention (CDC), National Center on Birth Defects and Developmental Disabilities (NCBDDD). Whitehead N (PI). 2014 – 2019. • Global Lead Principal Investigator: A randomized, double-blind, placebo-controlled, multi- center study to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis (GMG), ECU-301, ECU-302, IND 101,219, EudraCT #2013- 003589-15. Alexion Pharmaceuticals, Inc. Howard JF (PI). 2014 – 2018. • Investigator: Autoimmune mechanisms in a novel Aire-deficient model of peripheral neuropathy. NIH/ Environmental Med, Asthma and Lung Biology, 1-R01-NS079683-01A1, Su, M (PI), 2013 — 2018. • Principal Site Investigator: Duchenne Muscular Dystrophy: Double-Blind Randomized Trial to find the optimum Steroid Regimen (FOR-DMD) NIH/NINDS U01-NS061799-01A2, Griggs B (PI), 2013 — 2021. • Co-Investigator: DP ARF Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy, NIH R01 NS074057-01A1, Gallippi C (PI), 2011 — 2017. GRANTS SUBMITTED (PENDING): • Principal Site Investigator: Characterization of T cell responses in inclusion body myositis. NIH Exploratory/Developmental Research Grant Program (Parent R21). Guptill, J (PI). GRANTS FUNDED (COMPLETED): • Principal Site Investigator: Exploratory Study of Immunological Profiles in Myasthenia Gravis Subjects that Receive Therapeutic Plasma Exchange. UCB Biosciences. Guptill, J (PI). 2014 — 2015. • Principal Site Investigator: BEL115123: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Patients with Myasthenia Gravis (MG). GlaxoSmithKline Pharmaceuticals, Inc., 2013 — 2015. • Principal Site Investigator: A phase II randomized, double-blinded, controlled trial of methotrexate versus placebo in Myasthenia Gravis patients who are considered steroid dependent. NIH/NINDS (University of Kansas), R01FD003538, Barohn R (PI), 2011 — 2014. Curriculum Vitae November 6, 2017 Howard, James F., Jr. Page 4 • Investigator: Safety and Feasibility of Transvenous Limb Perfusion with Normal Saline in Human Muscular Dystrophy, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, NIH/NIAMS 1U54AR056953-01, Powers WJ (PI), 2008 — 2013. • Principal Site Investigator: A Phase II, Randomized, Three-Way Crossover, Placebo- Controlled, Pharmacodynamic Study of CK-2107357 in Patients with Generalized Myasthenia Gravis on Standard Therapy, Cytokinetics, Inc., CY 4023/ NINDS 1RC3NS070670-01; CFDA Number: 93.71, 2011 — 2013. • Co-Investigator: Automated Atlas-based Muscle MRI Quantification in Duchenne Muscular Dystrophy Patients, NC TraCS # 50KR71104, University of North Carolina, Fan Z (PI), 2011 — 2012. • Principal Site Investigator: A randomized, double-blind, placebo-controlled, cross-over, multi-center study of eculizumab in patients with generalized myasthenia gravis (GMG) who have moderate to severe weakness despite treatment with immunosuppressants. Alexion Pharmaceuticals, Inc., C08-001, 2008 — 2012. • Principal Site Investigator: Genome wide association study in Myasthenia Gravis. Myasthenia Gravis Foundation of America, 2010 — 2011. • Consultant: Pilot evaluation of the effects of substance P-saporin (SP-SAP) on chronic pain due to osteoarthritis in companion dogs. (PI: Olby, Natasha & Lascelles, Duncan), Novartis, 2010 — 2011. • Consultant: Development of a technique for measuring canine phrenic nerve conduction velocity. (PI: Olby, Natasha & Matthews, Kyle), NCSU, 2010 — 2011. • Investigator: Pudendal Nerve Function as a Predictor of Female Sexual Function with Sacral Neuromodulation. (PI: Parnell, B.) American Urogynecologic Society, 2010 — 2011. • Investigator: National Center for Canine Models of Duchene Muscular Dystrophy ARRA, NIH/NINDS 3-U24-NS059696-01A1S1, 2009 — 2011 • Sub-Investigator: The Natural History of Infantile Globoid Cell Leukodystrophy. Zymenex A/S, rhGALC-01, 2009 — 2011. • Sub-Investigator: The Natural History of Metachromatic Leukodystrophy. Zymenex A/S, 2008 — 2011. • Principal Investigator: Investigation of the ability of Otelixizumab to inhibit in vitro antigen- specific T cell responses from Myasthenia Gravis patients. GlaxoSmithKline Pharmaceuticals, Inc., MGO113510, 2010. • Consultant: Prednisone
Load more

Recommended publications
  • Neuromuscular Disorders Neurology in Practice: Series Editors: Robert A
    Neuromuscular Disorders neurology in practice: series editors: robert a. gross, department of neurology, university of rochester medical center, rochester, ny, usa jonathan w. mink, department of neurology, university of rochester medical center,rochester, ny, usa Neuromuscular Disorders edited by Rabi N. Tawil, MD Professor of Neurology University of Rochester Medical Center Rochester, NY, USA Shannon Venance, MD, PhD, FRCPCP Associate Professor of Neurology The University of Western Ontario London, Ontario, Canada A John Wiley & Sons, Ltd., Publication This edition fi rst published 2011, ® 2011 by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientifi c, Technical and Medical business to form Wiley-Blackwell. Registered offi ce: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offi ces: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offi ces, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identifi ed as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • CAP-1002 for Advanced DMD: a New Treatment Option
    CAP-1002 for Advanced DMD: A New Treatment Option October 24, 2019 NASDAQ: CAPR Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 29, 2019, and as amended by its Amendment No.
    [Show full text]
  • Neuromuscular Disorders of Infancy, Childhood, and Adolescence
    Chapter 1 Introduction: Historical Perspectives Darryl C. De Vivo, Basil T. Darras, Monique M. Ryan, and H. Royden Jones, Jr. INTRODUCTION infancy, childhood, and adolescence. Nevertheless, these traditional tests remain useful in certain situations: to The role of the clinician in the diagnosis and treatment of evaluate patients in whom molecular genetic analyses fail a weak child is as important today as it was in the 19th to confirm the initial clinical impression, to facilitate the century, when pediatric neuromuscular diseases were first 1 rapid electrophysiologic diagnosis of a neuropathy or being recognized by such luminaries as Meryon (1852), spinal muscular atrophy, or to focus more precisely on Duchenne (1861),2 Werdnig (1891),3 and Hoffmann 4 5 molecular mechanisms before ordering relatively expen- (1893), and later by Batten (1903). The clinician needs sive molecular genetic tests. The dramatic advances in to react to the concerns of the patient and their parents at DNA diagnostics have added to the complexity of a chal- the first encounter. A detailed medical history and care- lenging clinical field and have left physicians occasion- fully performed physical examination remain the funda- ally uncertain about the relative indications for traditional mental tools and starting point for assessing various tests such as EMG and muscle biopsy. Clearly, all these symptoms and signs. This initial clinical assessment has diagnostic tests remain useful, and it is up to the modern three possible immediate outcomes: (1) the concerns of clinician to make informed decisions, after the initial clin- the patient and family appear to be unfounded, and the ical evaluation, to facilitate an accurate biomolecular clinician can be reassuring.
    [Show full text]
  • Recommended Policy for Electrodiagnostic Medicine
    Recommended Policy for Electrodiagnostic Medicine Executive Summary The electrodiagnostic medicine (EDX) evaluation is an important and useful extension of the clinical evaluation of patients with disorders of the peripheral and/or central nervous system. EDX tests are often crucial to evaluating symptoms, arriving at a proper diagnosis, and in following a disease process and its response to treatment in patients with neuromuscular (NM) disorders. Unfortunately, EDX studies are poorly understood by many in the medical and lay communities. Even more unfortunately, these studies have occasionally been abused by some providers, resulting in overutilization and inappropriate consumption of scarce health resources. The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) has developed this model policy to improve the quality of patient care, to encourage appropriate utilization of the procedures involved, and to assist public and private insurance carriers in developing policy regarding EDX testing. This document contains recommendations which can be used in developing and revising current reimbursement guidelines. This document is based on the AANEM’s prior publications on appropriate EDX evaluations and was further refined by consensus at a conference of 43 experts in the field of EDX medicine. This consensus conference was held to produce guidelines that could be used to identify overutilization. Participants in the conference represented a diversity of practice types and were either neurologists or physiatrists and included the AANEM Board of Directors, committee chairs, Professional Practice Committee members, and other members of the association. Physicians from both academic medical centers and private practice were represented. With the help of the AANEM Professional Practice Committee, the guidelines have continuously been revised to produce this comprehensive policy regarding the optimal use of EDX procedures.
    [Show full text]
  • Neuromuscular Medicine Core Competencies Outline
    The American Board of Psychiatry and Neurology Neuromuscular Medicine Core Competencies Outline I. Neuromuscular Patient Care Core Competencies A. GENERAL: Neuromuscular Medicine Specialists shall demonstrate the following abilities: 1. To perform and document relevant history and examination of culturally diverse patient to include as appropriate: a. Chief complaint b. History of present illness c. Past medical history d. Developmental history (especially for children) e. Comprehensive review of both neurologic and general systems f. Biological family history g. Sociocultural history h. Neurological examination and a germane general examination as appropriate to the present illness 2. Delineate appropriate differential diagnoses 3. Formulate, assess and recommend effective management B. FOR NEUROMUSCULAR MEDICINE: Based on comprehensive neurological assessments, Neuromuscular Specialists shall demonstrate the following abilities: 1. To determine: a. If a patient’s symptoms are the result of a disease affecting the central and/or peripheral nervous system or are of another origin (e.g., of a systemic, psychiatric, or psychogenic illness) by performing appropriate neuromuscular evaluation b. An initial diagnostic formulation with differential diagnosis c. Appropriate diagnostic modalities to include laboratory blood, urine, and cerebrospinal fluid analyses, electrodiagnostic, imaging, genetic, and pathologic investigations to evaluate and manage such patients d. Management plan 2. To develop and maintain the technical skills to: a. Perform
    [Show full text]
  • University of Kansas Neuromuscular Fellowship Program Goals, Objectives and Competencies by Rotation
    UNIVERSITY OF KANSAS NEUROMUSCULAR FELLOWSHIP PROGRAM GOALS, OBJECTIVES AND COMPETENCIES BY ROTATION The goal of the training in Neuromuscular Medicine is to provide the resident with the opportunity to develop the expertise necessary to evaluate and manage patients with neuromuscular disorders using specialized procedures and techniques. It is the intent of the Neuromuscular Medicine training program to develop neurologists and physical medicine rehabilitation specialist into competent neuromuscular specialists. Neurologists / physiatrists successfully completing the program will be eligible for Neuromuscular Medicine subspecialty certification by the American Board of Psychiatry and Neurology. The objective is to provide residents with the opportunity to develop the expertise necessary to evaluate and manage patients using the procedures and techniques of Neuromuscular Medicine and that all trainees will pass the examination. Neuromuscular Medicine includes the assessment of selective neurological disorders involving central, peripheral and autonomic nervous systems and muscles. Assessment, monitoring and treatment are involved in electrophysiological testing in combination with clinical evaluation. The goals of the training program include extensive experience in neuromuscular clinical evaluation, rehabilitation, nerve and muscle pathology, motor and sensory conduction studies and diagnostic electromyography. Familiarity with single fiber electromyography, skin pathology and autonomic function is included. Clinical competence in Neuromuscular Medicine requires: a. A solid fund of basic clinical knowledge and the ability to maintain it at current levels for a lifetime of continuous education b. The ability to perform an adequate history and physical examination c. The ability to appropriately order and interpret diagnostic tests d. Adequate technical skills to carry out selected diagnostic procedures e. Clinical judgment to critically apply the above data to individual patients f.
    [Show full text]
  • Iatrogenic Neuromuscular Disorders
    Iatrogenic Neuromuscular Disorders Peter D. Donofrio, MD Anthony A. Amato, MD James F. Howard, Jr., MD Charles F. Bolton, MD, FRCP(C) 2009 COURSE G AANEM 56th Annual Meeting San Diego, California Copyright © October 2009 American Association of Neuromuscular & Electrodiagnostic Medicine 2621 Superior Drive NW Rochester, MN 55901 Printed by Johnson Printing Company, Inc. ii Iatrogenic Neuromuscular Disorders Faculty Anthony A. Amato, MD Charles F. Bolton, MD, FRCP(C) Department of Neurology Faculty Brigham and Women’s Hospital Department of Medicine Division of Neurology Harvard Medical School Queen’s University Boston, Massachusetts Kingston, Ontario, Canada Dr. Amato is the vice-chairman of the department of neurology and the Dr. Bolton was born in Outlook, Saskatchewan, Canada. He received director of the neuromuscular division and clinical neurophysiology labo- his medical degree from Queen’s University and trained in neurology ratory at Brigham and Women’s Hospital (BWH/MGH) in Boston. He is at the University Hospital, Saskatoon, Saskatchewan, Canada, and at also professor of neurology at Harvard Medical School. He is the director the Mayo Clinic. While at Mayo Clinic, he studied neuromuscular of the Partners Neuromuscular Medicine fellowship program. Dr. Amato disease under Dr. Peter Dyck, and electromyography under Dr. Edward is an author or co-author on over 150 published articles, chapters, and Lambert. Dr. Bolton has had academic appointments at the Universities books. He co-wrote the textbook Neuromuscular Disorders with Dr. Jim of Saskatchewan and Western Ontario, at the Mayo Clinic, and cur- Russell. He has been involved in clinical research trials involving patients rently at Queen’s University.
    [Show full text]
  • Shaped Neuromuscular Disease in North America Richard J
    How the Vietnam War, Communism, Russia/USSR (and other despots) Shaped Neuromuscular Disease in North America Richard J. Barohn, M.D. Gertrude and Dewey Ziegler Professor of Neurology University Distinguished Professor Vice Chancellor for Research University of Kansas Medical Center Kansas City, KS KUMC Neurology Grand Rounds Kansas City, KS July 19th, 2019 Dr. Barohn served as a consultant for NuFactor and Momenta Pharmaceutical and receives research support from PTC Therapeutics, Ra Pharma, Orphazyme, Sanofi Genzyme, FDA OOPD, NIH, and PCORI. www.rrnmf.com > 2,000 Neuromuscular Health Care Professionals The Doctor Draft • The Doctor Draft began during Korean • Alternative to military: Public Health War-early 50s Service (PHS) as Commissioned • Continued during Vietnam War 1965- Officer-very selective 1973 • Could serve in PHS at various • Two year commitment to military locations armed forces -PHS Hospitals in major cities • Berry plan allowed doctors to defer -Indian Health Service Hospitals service until after training -National Communicable Disease Center (future CDC) -National Center for Urban and Industrial Health -NIH NIH Associate Training Program-ATP • Began in 1950s • Assigned to a Senior Staff • Clinical or Research or Staff Investigator/mentor Associates • Very competitive • After completing at least two • Associates chosen by the post doctoral years of Institute Scientific Director training/residency Number of Participants in NIH ATP • 1960: #68 associates • 1964-Gulf of Tonkin Resolution, authorizing The New president to
    [Show full text]
  • AANEM Foundation Steps up Funding for Research He AANEM Foundation Has Made Significant Steps Toward the Funds
    Newsletter of the American Association of Volume 10 | Issue 1 AANEM • February 2017 • 1 Neuromuscular & Electrodiagnostic Medicine February 2017 INSPIRE THE NEXT GENERATION 4 ANNUAL MEETING 7 LABORATORY ACCREDITATION 11 2017 PHYSICIAN FEE SCHEDULE 15 AANEM Foundation Steps Up Funding for Research he AANEM Foundation has made significant steps toward the funds. We hope that the membership will see the need for Tfunding research in neuromuscular medicine. Thanks to our these and help fund these programs.” partnership with the Muscular Dystrophy Association (MDA), the AANEM is currently co-funding three studies: Funding Commitments • LncRNA as therapeutic target for SMA by Constantin In order to provide long term funding for two to three projects d’Ydewalle, PhD of about $120,000 per year, the AANEM transferred $3 million • Improving the diagnosis of NM diseases by Monkol Lek, to the Foundation. “The AANEM is committed to supporting PhD research, as demonstrated by this transfer of money to the • Motor system connectivity influences in ALS by Christi Foundation,” said William S. Pease, MD, AANEM President. Kolarcik, PhD “This amount, however, only begins this commitment by funding two projects with the MDA and one project through AANEM. Read interviews with Drs. Lek and Kolarcik on pages 16-17, and There are many more great research ideas that we are unable to detailed project summaries at www.aanemfoundation.org/Research- fund. Please consider donating to the AANEM Foundation to Grants/Currently-Funded-Projects. help us advance neuromuscular medicine through research that will someday lead to improved treatments for our patients.” In addition to the partnership with MDA, the Foundation is funding its own development grants.
    [Show full text]
  • Neurophysiologic Testing and Monitoring
    UnitedHealthcare® Value & Balance Exchange Medical Policy Neurophysiologic Testing and Monitoring Policy Number: IEXT0152.02 Effective Date: March 1, 2021 Instructions for Use Table of Contents Page Related Policies Applicable States ........................................................................... 1 None Coverage Rationale ....................................................................... 1 Applicable Codes .......................................................................... 2 Description of Services ................................................................. 4 Clinical Evidence ........................................................................... 6 U.S. Food and Drug Administration ........................................... 17 Centers for Medicare and Medicaid Services ........................... 19 References ................................................................................... 19 Policy History/Revision Information ........................................... 23 Instructions for Use ..................................................................... 23 Applicable States This Medical Policy only applies to the states of Arizona, Maryland, North Carolina, Oklahoma, Tennessee, Virginia, and Washington. Coverage Rationale Nerve Conduction Studies The following are proven and medically necessary: Nerve conduction studies with or without late responses (e.g., F-wave and H-reflex tests) and neuromuscular junction testing when performed in conjunction with needle electromyography for any of
    [Show full text]
  • Facioscapulohumeral Muscular Dystrophy: Genetics and Trials Robin Warner
    Chapter Facioscapulohumeral Muscular Dystrophy: Genetics and Trials Robin Warner Abstract A complex combination of molecular pathways and cell interactions causes facioscapulohumeral muscular dystrophy (FSHD). Several new therapies pose a promising solution to this disease with no cure. This chapter aims to explain the genetics of facioscapulohumeral muscular dystrophy, and review the current clini- cal trials for the treatment of FSHD. Keywords: facioscapulohumeral muscular dystrophy, antisense oligonucleotide, decoy nucleic acid, novel therapies, genetics, trials 1. Introduction 1.1 Epidemiology Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common muscular dystrophies. Worldwide, its prevalence is up to 6.8 in 100,000 and in the United States, it is about 1 in 20,000. It affects men more than women because estrogens counteract the differentiation impairment of FSHD myoblasts without affecting cell proliferation or survival. Estrogen effects are mediated by estrogen receptor β (ERβ), which reduces chromatin occupancy and transcriptional activity of double homeobox 4 (DUX4) [1]. 1.2 History Facioscapulohumeral muscular dystrophy was first described by two French physicians, Louis Landouzy and Joseph Jules Dejerine, in the late 1800s [2]. Their description was based on a family that they had monitored for 11 years. In 1950, Tyler and Stephens described a family from Utah that included 1249 people span- ning six generations. All were descendants of an affected individual who had migrated to Utah in 1840. Their findings
    [Show full text]
  • Neuromuscular Medicine Fellowship Curriculum
    Neuromuscular Medicine Fellowship Curriculum General ● Review Goals and Objectives ● Attend weekly EMG sessions as assigned ● Take a Directed History and Exam of each EMG patient ● Attend every other week Muscle Disease Clinic (Tues AM) ● Attend every Wed AM Neuromuscular Clinic ● Attend weekly neuropathology session (Wed PM) ● Attend Weekly neuromuscular/EMG didactic lecture (Friday AM) ● Follow Inpatient Neuromuscular admissions and consults with attendings ● Attend monthly nerve and muscle biopsy Conference with NM Faculty ● Attend and participate actively Friday Noon NM Conference ● Prepare and present recent papers in weekly NM Journal Club (Wed Noon) ● Prepare and present at the biweekly NM disorder didactic conference (Tues AM) ● Present at Neurology Grand Rounds (third quarter) Lectures ● Wednesday PM Journal club ● Friday Noon neuromuscular/EMG didactic lecture ● Friday AM Neurology Grand Rounds ● Tuesday AM NM disorder didactic ● Assigned Readings: ● Katirji et al. Neuromuscular Disorders in Clinical Practice, B-H, 2002 (NMDCP) ● Preston and Shapiro. EMG and Neuromuscular Disorders, Elsevier, 2005 (P&S) ● Katirji B. Electromyography in Clinical Practice, Elsevier, 2007 (BK) ● Aids to the Examination of the Peripheral Nervous System (ATEPNS) Month 1-3 ● Read BK Chapters 1-4 Introduction to clinical EMG Routine Clinical EMG Specialized EDX studies EDX findings in neuromuscular diseases ● Read P&S Chapters 1-4, 7, 8 Approach to NCS and EMG Anatomy and Physiology Basic Nerve Conduction Studies Late Responses Anomalous Innervations
    [Show full text]